ストックスクリーナーアプリを入手
121.84
0.27%
0.33
アフターアワーズ：
121.37
-0.47
-0.39%
前日終値:
$121.51
開ける：
$122.19
24時間の取引高:
2.08M
Relative Volume:
0.95
時価総額：
$13.83B
収益：
$1.51B
当期純損益:
$348.84M
株価収益率:
43.82
EPS:
2.7805
ネットキャッシュフロー:
$667.65M
1週間 パフォーマンス:
+10.34%
1か月 パフォーマンス:
+12.36%
6か月 パフォーマンス:
+82.83%
1年 パフォーマンス:
+82.18%
1日の値動き範囲:
$120.19
$122.44
1週間の範囲:
$108.80
$122.44
52週間の値動き範囲:
$61.23
$122.44
Halozyme Therapeutics Inc Stock (HALO) Company Profile
名前
Halozyme Therapeutics Inc
セクター
電話
(858) 794-8889
住所
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
121.84 | 13.83B | 1.51B | 348.84M | 667.65M | 2.7805 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-08-07 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-12-04 | ダウングレード | Goldman | Neutral → Sell |
| 2025-10-14 | アップグレード | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | 再開されました | Goldman | Neutral |
| 2025-05-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | ダウングレード | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-06-07 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 開始されました | TD Cowen | Outperform |
| 2023-07-24 | ダウングレード | Goldman | Buy → Neutral |
| 2023-07-24 | 開始されました | H.C. Wainwright | Buy |
| 2023-05-10 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 再開されました | Berenberg | Buy |
| 2023-03-16 | ダウングレード | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 再開されました | Morgan Stanley | Overweight |
| 2022-11-28 | 開始されました | Wells Fargo | Overweight |
| 2022-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2021-06-14 | 開始されました | Evercore ISI | Outperform |
| 2021-05-17 | 開始されました | SVB Leerink | Outperform |
| 2021-05-11 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 繰り返されました | The Benchmark Company | Buy |
| 2020-12-17 | 開始されました | Berenberg | Buy |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-07-01 | 開始されました | The Benchmark Company | Buy |
| 2020-02-05 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 開始されました | Goldman | Buy |
| 2019-11-05 | アップグレード | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 再開されました | Piper Jaffray | Neutral |
| 2018-05-11 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 開始されました | Goldman | Neutral |
| 2017-10-16 | 繰り返されました | Piper Jaffray | Overweight |
| 2017-01-06 | ダウングレード | Citigroup | Buy → Neutral |
| 2016-11-03 | 開始されました | Deutsche Bank | Buy |
| 2015-12-04 | 開始されました | Wells Fargo | Outperform |
| 2015-11-18 | 開始されました | Citigroup | Buy |
| 2015-09-22 | 開始されました | Barclays | Overweight |
| 2015-06-22 | 繰り返されました | JP Morgan | Overweight |
| 2015-03-03 | 繰り返されました | UBS | Buy |
| 2015-02-18 | 繰り返されました | MLV & Co | Buy |
| 2015-01-08 | 繰り返されました | MLV & Co | Buy |
すべてを表示
Halozyme Therapeutics Inc (HALO) 最新ニュース
5 Stocks to Buy Using the Relative Price Strength Strategy - Zacks Investment Research
KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome - Zacks Investment Research
Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains - Zacks Investment Research
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Zacks Investment Research
Top Research Reports for Mastercard, AstraZeneca & Sandisk - Zacks Investment Research
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) - Zacks Investment Research
Why Investors Need to Take Advantage of These 2 Medical Stocks Now - Zacks Investment Research
Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
Halozyme director Matthew Posard sells $567,660 of common stock - Investing.com
Form 4 Halozyme Therapeutics Inc: Matthew L. Posard (Director) For: 1 October - Investing.com Canada
Form 4 Halozyme Therapeutics Inc: Matthew L. Posard (Director) For: 1 October - Investing.com India
Halozyme Therapeutics, Inc. (HALO) Stock Forecasts - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO) Stock forecasts - Yahoo Finance UK
Halozyme Therapeutics (NASDAQ:HALO): A Decent Value Stock With Strong Profitability - ChartMill
Halozyme Therapeutics Insider Sold Shares Worth $6,610,501, According to a Recent SEC Filing - www.marketscreener.com
Form 4 Halozyme Therapeutics Inc For: 8 October By Investing.com - Investing.com Nigeria
HALO Maintained by JP Morgan -- Price Target Raised to $78.00 - GuruFocus
A director received 3,796 stock units at Halozyme (HALO), not the 6,796 originally reported. - Stock Titan
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe - Zacks Investment Research
Halozyme Therapeutics, Inc. (HALO) Stock Forecasts - Yahoo Finance
HALO Maintains Buy Rating -- Price Target Raised to $130 by HC Wainwright - GuruFocus
Halozyme Therapeutics (HALO) Expands Argenx Deal, Is It Still 27% Below Fair Value? - Yahoo! Finance Canada
Halozyme Therapeutics (HALO) Expands Argenx Deal, Is It Still 27% Below Fair Value? - Yahoo Finance
Merck’s Keytruda Is Dealt a Legal Setback. It’s Good News for This Biotech Stock. - Barron's
Halozyme wins court order to block Merck's injected Keytruda in select European markets - Reuters
Halozyme stock rises after winning injunction against Merck - Yahoo Finance
HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX - Zacks Investment Research
HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX - TradingView
Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets - PR Newswire
HALOThe $300+ Runway: Why Halozyme’s Pipeline Transition Erases the Patent Cliff - Simply Wall Street
Halozyme Therapeutics, Inc. (HALO) Stock forecasts - Yahoo Finance Singapore
A drug-delivery partnership expands from six exclusive targets to eight. - Stock Titan
Halozyme Therapeutics, Inc. And Argenx Announce Expansion Of Global Collaboration And License Agreement To Support The Development Of Subcutaneous Formulations For Two Additional Exclusive Targets Using ENHANZE® Technology - www.marketscreener.com
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® Technology - PR Newswire
Halozyme Therapeutics, Inc. - Simply Wall Street
Halozyme Therapeutics (NASDAQ:HALO): High Growth Momentum Meets Breakout Setup - ChartMill
Director Daly’s 1,169-unit stock grant at Halozyme (HALO) is scheduled to vest at the 2027 annual meeting. - Stock Titan
Halozyme Therapeutics Insider Sold Shares Worth $567,661, According to a Recent SEC Filing - marketscreener.com
[Form 3] HALOZYME THERAPEUTICS, INC. Initial Statement of Beneficial Ownership - Stock Titan
Under a trading plan, director Matthew L. Posard sells 5,230 Halozyme (HALO) shares. - Stock Titan
Unpacking Q2 Earnings: Halozyme Therapeutics (NASDAQ:HALO) In The Context Of Other Therapeutics Stocks - Yahoo Finance
Halozyme Therapeutics, Inc. (HALO) Stock Forecasts - Yahoo! Finance Canada
Halozyme appoints Jim Daly to board of directors By Investing.com - Investing.com Nigeria
Halozyme Announces Appointment of Jim Daly to its Board of Directors - PR Newswire
Halozyme Therapeutics, Inc. Appoints James "Jim" Daly to Its Board of Directors - marketscreener.com
Price to cash flow ratio of Halozyme Therapeutics, Inc. – HAN:RV7 - TradingView
Halozyme Therapeutics, Inc. (HALO) Stock forecasts - Yahoo Finance Australia
Halozyme Therapeutics, Inc. Revenue Breakdown – HAN:RV7 - TradingView
Halozyme Therapeutics, Inc. Actuals & Estimates (HAN:RV7) - TradingView
ETFs Investing in Halozyme Therapeutics, Inc. Stocks - TradingView
Halozyme Therapeutics Inc (HALO) 財務データ
収益
当期純利益
現金流量
EPS
Halozyme Therapeutics Inc (HALO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Oct 08 '26 |
Sale |
109.40 |
20,000 |
2,187,909 |
767,780 |
| Torley Helen | PRESIDENT AND CEO |
Oct 08 '26 |
Option Exercise |
18.41 |
20,000 |
368,200 |
787,780 |
| Torley Helen | PRESIDENT AND CEO |
Oct 07 '26 |
Option Exercise |
18.41 |
20,000 |
368,200 |
787,780 |
| Torley Helen | PRESIDENT AND CEO |
Oct 07 '26 |
Sale |
111.55 |
20,000 |
2,231,049 |
767,780 |
| Torley Helen | PRESIDENT AND CEO |
Oct 06 '26 |
Sale |
109.58 |
20,000 |
2,191,543 |
767,780 |
| Posard Matthew L. | Director |
Oct 01 '26 |
Sale |
108.54 |
5,230 |
567,661 |
53,609 |
| MATTHEW POSARD | Director |
Sep 16 '26 |
Proposed Sale |
106.25 |
34,226 |
3,636,512 |
0 |
| Posard Matthew L. | Director |
Sep 16 '26 |
Sale |
107.74 |
18,996 |
2,046,581 |
58,839 |
| Torley Helen | PRESIDENT AND CEO |
Sep 11 '26 |
Sale |
107.24 |
20,000 |
2,144,856 |
767,780 |
| Torley Helen | PRESIDENT AND CEO |
Sep 11 '26 |
Option Exercise |
18.41 |
20,000 |
368,200 |
787,780 |
1.95%
大文字化:
|
ボリューム (24 時間):